Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19951285 | 0.87 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2GAANPSR1POLB | |
| SCHEMBL19951292 | 0.84 | ALDH1A1 (0.68) | ALDH1A1SMN1; SMN2GAANPSR1POLB | |
| SCHEMBL19951266 | 0.81 | KDM4E (0.47) | ALDH1A1SMN1; SMN2GAANPSR1POLB | |
| SCHEMBL19951229 | 0.77 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2GAANPSR1POLB | |
| SCHEMBL19951248 | 0.77 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2GAANPSR1POLB | |
| SCHEMBL16832318 | 0.72 | SMN1; SMN2 (0.69) | ALDH1A1SMN1; SMN2GAAHTTLMNA | |
| SCHEMBL16832567 | 0.72 | MAPT (0.67) | ALDH1A1SMN1; SMN2GAANPSR1HTT | |
| SCHEMBL16832427 | 0.72 | ALDH1A1 (0.70) | ALDH1A1SMN1; SMN2GAAHTTLMNA | |
| SCHEMBL16832413 | 0.72 | LMNA (0.56) | ALDH1A1SMN1; SMN2GAAMAPTLMNA | |
| SCHEMBL19951277 | 0.71 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2GAANPSR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10357477-B2 | Anticancer compounds | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2019-07-23 | — | — | US | disclosed |
| US-20180071258-A1 | ANTICANCER COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071258-A1 | ANTICANCER COMPOUNDS | RB1, MCL1, TP53 | ALDH1A1 757/4885SMN1; SMN2 2882/4885GAA 1917/4885 |
| US-10357477-B2 | Anticancer compounds | RB1, MCL1, TP53 | ALDH1A1 757/4885SMN1; SMN2 2882/4885GAA 1917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.